A Study of LM-24C5 For Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
LaNova Medicines Limited
Study ID
NCT06187402
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LM-24C5 — DRUG
    Administered intravenously

Study Details

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

Key Dates

Start date
Dec 20, 2023
Status verified
Sep 2025
Primary completion
Jun 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
49 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LM-24C5 Dose Escalation
  • Experimental: LM-24C5 Dose Expansion

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: 60 weeks ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
University of Southern California (USC) - Norris Comprehensive Cancer CenterLos AngelesCalifornia90089
Heinz-Josef Lenz
Ocala OncologyOcalaFlorida34474
Rama Balaraman
Indiana University Melvan and Bren Simon Cancer CenterIndianapolisIndiana46202
Mateusz Opyrchal
The Christ HospitalCincinnatiOhio45219
Alex Starodub
Mary Crowley Cancer Research CenterDallasTexas75230
Minal Barve
Virginia Cancer Specialists, P.C.FairfaxVirginia22031
Alexander Spira

Find similar trials in Los Angeles, CA

By research site
University of Southern California (USC) - Norris Comprehensive Cancer Center· Los Angeles, CAOcala Oncology· Ocala, FLIndiana University Melvan and Bren Simon Cancer Center· Indianapolis, INThe Christ Hospital· Cincinnati, OHMary Crowley Cancer Research Center· Dallas, TXVirginia Cancer Specialists, P.C.· Fairfax, VA

Related Studies